This study is to confirm the role of glycyrrhizin on blood pressure and to test the effects of glycyrrhizin on production of vascular aldosterone and corticosterone in rats. Male Wistar rats received glycyrrhizin (Sigma) 200 mg/kg/day p.o. for 5 weeks, and blood pressure was monitored by a pressure transducer. Systolic blood pressure significantly increased in Wistar rats treated with glycyrrhizin compared to that without glycyrrhizin. Mesenteric artery perfusion ex vivo and pressor responses to norepinephrine were performed. The pressor responses to norepinephrine in mesenteric arteries treated with glycyrrhizin were significantly increased. The perfusate from the mesenteric arteries was collected and applied to a Sep-Pak C 18 cartridge column, used for reverse-phase high-performance liquid chromatography, and measured for both aldosterone and corticosterone by radioimmunoassay. Levels of aldosterone were decreased but those of corticosterone increased in perfusate from arteries treated with glycyrrhizin. RT-PCR showed that glycyrrhizin inhibited the expression of 11β- HSD2 and CYP11B2 mRNA in mesenteric arteries. These results confirm that glycyrrhizin is able to induce hypertension, and provide evidence that it inhibits the transcriptions of both 11β-HSD2 and CYP11B2 in the vasculature, leading to lower aldosterone and higher corticosterone production in vessels, and increased vasoconstrictor responses to norepinephrine.

Keywords:
Glycyrrhizin, Hypertension, 11β-Hydroxysteroid dehydrogenase, Aldosterone synthase
1.
White PC, Obeid J, Agarwal AK, Tannin GM, Nikkila H: Genetic analysis of 11β-hydroxysteroid dehydrogenase. Steroids 1994;59:111–115.
2.
Funder JW, Pearce PT, Smith R, Smith AI: Mineralocorticoid action: Target tissue specificity is enzyme, not receptor, mediated. Science 1988;242:583–585.
3.
Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, De-kloet ER, Monder C: Localisation of 11β-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 1988;ii:986–989.
4.
Monder C, White PC: 11Beta-hydroxysteroid dehydrogenase. Vitam Horm 1993;47:187–271.
5.
White PC, Mune T, Rogerson FM, Kayes KM, Agarwal AK: 11Beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess. Pediatr Res 1997;41:25–29.
6.
Krozowski Z: The 11beta-hydroxysteroid dehydrogenase enzymes: Perspectives and paradoxes. Endocr Res 1996;22:781–790.
7.
Miyamori I, Takeda Y, Yasuhara S, Ikeda M, Takeda R: Participation of vascular prostacyclin of experimental glucocorticoid hypertension in rats. Clin Exp Hypertens 1985;A7:513–524.
8.
Oaks Mk, Raff H: Differentiation of the expression of aldosterone synthase and 11β-hydroxylase mRNA in the rat adrenal cortex by reverse transcriptase polymerase chain reaction. J Steroid Biochem Mol Biol 1995;54:193–199.
9.
Ming YZ, Elise P, Gomez S, Diana L, Cox DC, Gomez SCE: Cloning, expression, and tissue distribution of the rat nicotinamide ade- nine dinucleotide-dependent 11 β-hydroxyste- roid dehydrogenase. Endocrinology 1995;136:3729–3734.
10.
Junji N, Xi C, Hasna J: cAMP induces up-regulation of ETA receptor mRNA and increases responsiveness to endothelin-1 of rat aortic smooth muscle cells in primary culture. Biochem Biophys Res Commun 1992;188:719–726.
11.
Morris S: Licorice ingestion and blood pressure regulating hormones. Steroids 1994;59:127–129.
12.
Walker BR, Stewart PM, Shackleton CH, Padfield PL, Edwards CR: Deficient inactivation of cortisol by 11β-hydroxysteroid dehydrogenase in essential hypertension. Clin Endocrinol Oxf 1993;39:221–227.
13.
Takeda R, Takeda Y, Hatakeyama H, Iki K, Miyamori I, Wu PS, Yamamoto H, Blair IA: Aldosterone biosynthesis and action in vascular cells. Steroids 1995;60:120–124.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.